SCHEMBL21251808

SCHEMBL21251808

CCN1CCN(c2cc(C)c(Nc3cc4cnc(-c5c(F)c(OC)cc(OC)c5F)cc4cn3)c(NC)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 15/20 0.49
▸ FGFR4 P22455 13/20 0.49
▸ CHEK1 O14757 2/20 0.40
▸ FGFR2 P21802 4/20 0.35
▸ FGFR3 P22607 4/20 0.35
▸ PDGFRA P16234 2/20 0.35
▸ PDGFRB P09619 1/20 0.35
▸ JAK2 O60674 1/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ INSR P06213 1/20 0.34
▸ LCK P06239 1/20 0.34
▸ FYN P06241 1/20 0.34
▸ YES1 P07947 1/20 0.34
▸ LYN P07948 1/20 0.34
▸ RET P07949 1/20 0.34
▸ MET P08581 1/20 0.34
▸ ROS1 P08922 1/20 0.34
▸ KIT P10721 1/20 0.34
▸ BCR P11274 1/20 0.34
▸ SRC P12931 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21251976 0.91 FGFR1 (0.50) FGFR1FGFR4CHEK1FGFR2FGFR3
SCHEMBL21252339 0.90 FGFR1 (0.50) FGFR1FGFR4FGFR2FGFR3PDGFRA
SCHEMBL20330528 0.88 FGFR1 (0.66) FGFR1FGFR4FGFR2FGFR3
SCHEMBL30046401 0.88 FGFR1 (0.66) FGFR1FGFR4FGFR2FGFR3
SCHEMBL30045297 0.79 FGFR4 (0.66) FGFR1FGFR4FGFR2FGFR3
SCHEMBL20330526 0.79 FGFR4 (0.66) FGFR1FGFR4FGFR2FGFR3
SCHEMBL20330520 0.78 FGFR1 (0.65) FGFR1FGFR4FGFR2FGFR3
SCHEMBL30044812 0.78 FGFR1 (0.65) FGFR1FGFR4FGFR2FGFR3
SCHEMBL15618653 0.72 CCNA2 (0.43) FGFR1FGFR4CHEK1FGFR2SYK
SCHEMBL21252246 0.72 FGFR3 (0.46) FGFR1FGFR4CHEK1FGFR2FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3524603-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2019-08-14 — — EP disclosed
Send feedback